Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.
Epistemonikos ID: 90c24bfe664544b80e48ad2427ffc8fd7b7378aa
First added on: May 21, 2024